Venus Concept Inc
F:0RR1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.6), the stock would be worth €1.16 (451% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | €0.21 |
0%
|
| 3-Year Average | 1.6 | €1.16 |
+451%
|
| 5-Year Average | 4.6 | €3.26 |
+1 454%
|
| Industry Average | 3.3 | €2.29 |
+991%
|
| Country Average | 2.7 | €1.87 |
+792%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Venus Concept Inc
F:0RR1
|
499k EUR | 0.3 | -0 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 9.4 | 58.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3.1 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5.6 | 38.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 2.2 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 3.7 | 25.1 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 4.7 | 44.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 2.2 | 19 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 28.6 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 1.7 | 24.4 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.1 | 21.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
Venus Concept Inc
Glance View
Venus Concept, Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related practice enhancement services. The company is headquartered in Toronto, Ontario and currently employs 407 full-time employees. The company went IPO on 2017-10-12. The company develops, commercializes, and sells minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Freedom, Venus Viva, Venus Freeze Plus, Venus Glow, Venus Bliss, Venus Epileve and Venus Viva MD. Its hair restoration division includes NeoGraft, an automated hair restoration system that facilitates the harvesting of follicles during a Follicular unit extraction (FUE) process and the ARTAS and ARTAS iX Robotic Hair Restoration Systems, which harvests follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. The firm operates in the United States, Canada, United Kingdom, Japan, South Korea, Mexico, Argentina, Colombia, Spain, France, Germany, Australia, China, Hong Kong, and Israel.
